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Abstract: Traditional in vivo investigation of fungal infection and new antifungal therapies in
mouse models is usually carried out using post mortem methodologies. However, biomedical
imaging techniques focusing on non-invasive techniques using bioluminescent and fluorescent
proteins have become valuable tools. These new techniques address ethical concerns as they allow
reduction in the number of animals required to evaluate new antifungal therapies. They also allow
better understanding of the growth and spread of the pathogen during infection. In this review,
we concentrate on imaging technologies using different fungal reporter proteins. We discuss the
advantages and limitations of these different reporters and compare the efficacy of bioluminescent
and fluorescent proteins for fungal research.
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1. Fungi and Infection
Infections by fungi, e.g., Candida, Aspergillus and Cryptococcus species, are increasing threats to
human health [1]. Some fungal pathogens colonise particular sites in the human body and, most of
the time, do not cause harm to healthy individuals. However, these pathogens are significant threats
to immunocompromised patients when the immune system is no longer able to control colonisation
and infection develops. Life-threatening diseases, such as candidiasis or aspergillosis, mainly affect
severely immunocompromised hosts, and cryptococcosis occurs mainly in HIV/AIDS patients [1–3].
As eukaryotic pathogens causing a range of infections, pathogenic fungi present specific challenges to
human health and it is essential that we develop a better understanding of their pathogenicity and
interactions with the host.
Current antifungals to treat fungal infections are limited to four classes: polyenes, azoles,
echinocandins and 5-fluorocytosine (5-FC) [4,5], with amphotericin B (a polyene), fluconazole (an azole)
and 5-FC featuring on the WHO Essential Medicine List [6]. However, these drugs are not fully effective
in severe infections and are toxic to the patient [7,8]. The availability of amphotericin B and 5-FC
in certain countries in Africa with high burdens of fungal infection and the local high cost of other
antifungals, such as fluconazole, is also a global health issue [9,10]. Another issue in antifungal
treatment is the difference in efficacy of a drug in different fungal infections; e.g., echinocandin drugs,
such as caspofungin or micafungin, are effective against candidiasis [11,12]; however, they have no
impact on Cryptococcus infections [13]. Furthermore, the increasing incidence of drug resistance, such
as resistance to azoles and echinocandins in Candida and Aspergillus species, has become a severe
clinical challenge [14–16]. In addition, the emergence of new species, such as Candida auris, which are
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resistant to most of the currently available antifungals, are a growing health threat [17]. Due to the
limited availability of treatment choices, novel therapies are needed to improve patient outcome.
Rodent, mainly mouse, models of fungal infection have been central to efforts to evaluate novel
antifungal drugs. In vivo experiments allow essential understanding of pharmacokinetics and drug
susceptibility, although emerging in vitro model systems enable increasingly complex investigations of
interactions between host cells and fungi [18]. However, in vitro studies remain inherently limited in
their capacity to reproduce the complexity of living organisms. In fact, scientific breakthroughs for
some fungal pathogens have explicitly required animal models, e.g., Pneumocystis jirovecii, an obligate
biotroph of the lung [19]. Even among readily cultured fungal species, host-specific phenomena,
e.g., Cryptococcus neoformans titan cells [20], were only observed in hosts until the recent development
of novel in vitro models [21–23]. Likewise, discovery of the effect of carbon source on Candida albicans
virulence was first observed in murine infection models [24].
In addition to basic fungal biology insights that can be gained by studying these pathogens in the
context of the host, animal models are central to efforts to develop new chemotherapeutics. Animal
studies are mandatory for safety reasons, as some compounds, such as nystatin and amphotericin B,
possess outstanding activity in vitro but show toxicity once administered to a host [25]. A suitable
animal model is, therefore, essential to recognise the efficacy of any therapeutic agent, to optimise
its mode of delivery, and to assess drug–host interactions during treatment of fungal infections [26].
Traditional in vivo investigations of drug efficacy in mice usually involve post-mortem end point
methodologies, such as determining organ fungal burdens or measuring mouse survival during
treatment [26]. These methods have been the gold standard but can require large numbers of animals
to demonstrate drug efficacy. In addition, cryptic infection sites may be missed when these models
are used [27].
2. Novel Non-Invasive Techniques
Recently, non-invasive imaging techniques have been developed to monitor infection progression,
or resolution, allowing information to be obtained from individual animals over time [28,29].
In comparison with traditional protocols to measure drug efficacy, where groups of animals are sampled
at several time points during treatment and the average response is measured, non-invasive imaging
allows the response of each individual animal to be measured, reducing biological variation, and thus
reducing the number of animals required per group to evaluate any new antifungal drug. These novel
in vivo imaging techniques take advantage of bioluminescent or fluorescent proteins [30,31].
Bioluminescence refers to the light emitted from living organisms, which results from the oxidation
of organic substrates mediated by luciferases [31]. Bioluminescent imaging has the advantage of being
non-invasive, non-toxic for animals, and highly sensitive, with excellent signal-to-noise ratios [27].
However, a major drawback is the need to administer a substrate, such as luciferin. Attempts to
investigate systemic candidiasis using bioluminescent reporters have failed due to poor penetration of
the substrate in the mouse [32].
Fluorescent reporters emit light without injection of a substrate prior to imaging. Conventional
green fluorescent proteins (GFPs) are not suitable for mammalian deep tissue imaging due to
haemoglobin, water and skin melanin absorbing at the GFP emission wavelength, which leads to a high
background [30,32–34]. However, fluorescent proteins in the near-infrared spectrum (650–900nm) are
effective for in vivo imaging [33,35]. The proteins can be expressed in living cells and optical spectral
separation techniques are becoming more developed and more widespread in the near-infrared
spectrum [29,36,37].
This review describes challenges with bioluminescent imaging and advances in in vivo fluorescent
imaging for systemic and deep tissue fungal infections, as well as discussing challenges and
opportunities for widespread implementation of these technologies.
J. Fungi 2019, 5, 29 3 of 9
3. Key Challenges of In Vivo Imaging of Fungal Infections
There are a number of challenges to consider with in vivo imaging of pathogenic fungi.
The recurrent problem of signal-to-noise is very important, especially with deep-seated infections.
The presence of fatty tissue makes imaging more difficult as the excitation light must pass through the
different barriers to excite the target. The nature of the infections and the different host infection niches
have an important impact on the in vivo imaging strategies. Niches, such as the lung or brain, present
additional technical challenges due to the presence of the rib cage, bones and cartilage, which reduce
the transmission of light to the organ of interest. While localised infections can be visualised due to
the high concentration of reporter-tagged organisms, systemic infections can present the additional
challenge of a diffuse signal, requiring a brighter reporter to obtain a sufficient signal to monitor
infection [27,38].
In addition, reporters for in vivo imaging of systemic fungal infections require specific
optimisation, taking into consideration the different properties of fungi. For example, different
growth forms of some fungi have to be taken into account. The morphological yeast–hyphal switch
of certain pathogens, such as C. albicans, can represent a problem for quantification of the number
of fungi present, as it is difficult to quantify the number of cells in a mass of hyphae. The change in
morphology also represents a challenge for the construction of genetically encoded reporters as the
promoter driving expression may only be expressed in one growth form, e.g., a synthetic luciferase
was expressed in yeast but not in hyphae [39]. Another optimisation required for these reporters in
some fungi is codon optimisation. C. albicans, for example, has an alternative codon usage where CTG
codons, normally translated as leucine, are decoded as serine [40–42]. It is, therefore, necessary to
change every CTG codon to an appropriate leucine codon to accurately translate the reporter protein.
Cormack et al. [43] optimised a fully synthetic yeast-enhanced GFP gene (yEGFP3) for expression in
C. albicans based on codons frequently used by this species. This molecular optimization is required
for the construction and optimisation of any new reporter in C. albicans. However, lack of genome
information for less-studied pathogens, such as C. auris, represent another challenge for the expansion
of the use of fluorescent reporters in vivo.
4. Bioluminescent Imaging
Bioluminescent imaging relies on the detection of visible light, known as bioluminescence, which
arises from enzymatic oxidation of organic substrates by luciferases. Bioluminescence is seen in living
organisms, such as fireflies and luminous marine microorganisms [28]. Bioluminescent imaging has
the advantage of being highly sensitive, with excellent signal-to-noise ratios, and being non-invasive
and non-toxic for animals [31]. It requires construction of genetically-encoded reporters that express
proteins in living cells [31].
Three different luciferase genes have been developed to investigate fungal infections in living
animals. Firefly luciferase (fLUC) from Photinus pyralis [44] can be visualised across a spectrum from
yellow-green (550 nm) to red (620 nm). fLUC requires luciferin as a substrate, which is converted into
oxyluciferin in an ATP-dependent reaction [45]. In contrast, the sea pansy (Renilla reniformis) rLUC [46]
and the copepod Gaussia princeps gLUC [47] luciferases both use coelenterazine as their substrate
and emit light at 480 nm [32]. These fungal bioreporters were generated through strong synthetic
selection to enhance light emission compared to their parent bioluminescent molecules. Selection
of an appropriate promoter was also required to make these reporters capable of being expressed
within different fungal morphologies, such as C. albicans yeast and hyphal forms, to enable better
understanding of pathogen biology and virulence [32,38].
Luciferase reporters have been used in vitro for many years in investigation of gene regulation.
However, recent technological advances have allowed for the development of new, brighter reporters
for bioluminescence study of fungal infections [27,32,38]. One of the first luciferase-expressing fungal
species optimized for in vivo studies was reported by Doyle et al. [39], who developed a C. albicans
codon optimised fLUC reporter to visualise systemic and vulvovaginal candidiasis [39]. Despite
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promising preliminary data, a decrease in light output was observed when yeast cells switched to
a hyphal morphology [39]. This limitation encountered by Doyle et al. [39] could have been due to
the expressed luciferase being targeted to the cytoplasm of the fungal cell, but may also have been a
consequence of restricted luciferin permeability into C. albicans hyphae during infection [39,48].
To circumvent these problems, Enjalbert et al [32] created a cell surface-anchored Gaussia princeps
luciferase (gLUC) to ensure expression on the surface of both yeast and hyphal cells [32]. This
optimised reporter (emits at 480 nm) successfully enabled sensitive detection of C. albicans during
oropharyngeal and vulvovaginal candidiasis in mouse models [39,49,50], but was unsuitable for
imaging deep-seated infection due to a low signal-to-noise ratio at this wavelength. Dorsaz et al. [38]
using a cytoplasmic-expressed, codon-optimised red-shifted firefly luciferase in C. albicans detected
bioluminescent emissions in oropharyngeal candidiasis and also in systemic infection [38]. Although
this reporter improved the detection limits of C. albicans cells in infected mice, it required administration
of substrate D-luciferin immediately prior to imaging (10 minute in vivo), but signals in vivo were
detected in the kidneys during systemic infection and within the tongue during oropharyngeal
infection [38]. Similar results were obtained by Jacobsen et al. [27] where a codon-optimized firefly
luciferase (emits light at >600 nm) showed good correlation between light emission and fungal burdens
in C. albicans systemic infection [27]. A similar luciferase, optimized for expression in Candida glabrata,
was recently successfully used to demonstrate successful antifungal therapy of C. glabrata biofilms on
subcutaneously implanted catheters in mice [51]. Firefly luciferase is, therefore, considered the reporter
of choice as a dynamic and sensitive bioluminescent reporter, but its use still requires administration
of D-luciferin, which has to get into the fungal cells.
5. Fluorescent Imaging and iRFP
New technologies based on florescent and luminescent imaging have rapidly advanced in the
past decade [31]. Fluorescent reporters enable brighter visualisation and require shorter exposure
times than bioluminescence. Moreover, use of fluorescent proteins removes the need for substrates or
cofactors, allowing real-time analysis of whole systems using live imaging [28].
Fluorescent proteins are easily expressed in living cells. Genes encoding the fluorescent proteins
can be inserted into the fungal genome under the control of relevant promoters, providing valuable
information about the activation of transcriptional networks underlying pathogenesis in animal models,
which is already widespread in models of bacterial–host interactions [52,53].
Genetic engineering of different spectra, by changing the excitation and emission wavelengths of
the protein, enhanced brightness and overcame background noise, which was a key step in optimisation
of the first GFP reporter from Aequorea victoria (jellyfish) [54]. GFP derivatives were developed to emit
five main colours: cyan, green, yellow, orange and red. However, these light wavelengths are absorbed
by host tissue and, therefore, these reporters were not ideal for in vivo and deep tissue studies [55,56].
Fluorescent proteins emitting in the red and orange spectral region were originally developed
from the marine coral reef anemone Discosoma striata [57]. The first fluorescent protein to emit in the
red spectrum was DsRed, with an excitation peak at 558 nm and an emission peak at 583 nm [58].
DsRed has been expressed in Aspergillus and has proven to be a good reporter in vitro, but its faint
signal makes it difficult to work with in vivo [59,60]. In addition, there were problems associated with
the use of this new fluorescent protein, including incomplete maturation of DsRed. This was found
to be due to DsRed being an obligate tetramer, forming large protein aggregates in living cells [61].
Mutagenesis to overcome this problem led to a second generation of monomeric red fluorescent
proteins that avoided the problems of protein aggregates and toxicity [62]. mPlum, a monomeric
far-red fluorescent protein with emission at 649 nm, is one of these DsRed derivatives [63]. A second
promising fluorescent protein, HcRed, was isolated from the coral reef anemone Heteractis crispa [64].
HcRed is a dimer with a peak emission at 625 nm. Synthetic HcRed was engineered to encode two
tandem molecules to overcome intermolecular dimerisation, but efforts to create a monomeric version
by mutagenesis have been unsuccessful [64].
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6. Near-Infrared Fluorescent Protein
A promising technological advance in fluorescent reporters is based on work with a bacterial
phytochrome [33]. This phytochrome requires a cofactor, biliverdin, rather than a substrate to
produce fluorescence. Biliverdin is a bile pigment, abundant in the mammalian host as the initial
intermediate in haem catabolism [29,31,33]. IFP1.4 is a synthetic, optimised reporter that encodes
the chromophore-binding domain from the Deinococcus radiodurans phytochrome, with excitation
and emission maxima of 684 and 708 nm [33]. IFP1.4 is well expressed in mammalian cells and
mice and can be visualised with or without the addition of exogenous biliverdin [33]. Exogenous
addition increased near-infrared fluorescence, suggesting opportunities for further optimisation [33].
Subsequent mutagenesis generated a new, brighter near-infrared fluorescent protein (iRFP) with
excitation at 690 nm and emission at 713 nm [33]. Despite innovative results with iRFP to visualise
cells in vivo, the biliverdin cofactor limits its use, as biliverdin is absent in the lung and brain, limiting
use of this reporter for fungal infections found in these niches [35]. Moreover, in order to increase the
signal brightness, the fluorescent protein needs to be expressed on the surface of the cells to increase
the chance of binding with the cofactor.
These challenges may be overcome by the development of new bright reporters in the
near-infrared spectrum, which are capable of being activated when expressed within the cytoplasm
of the fungal cell. Scherbakova and Verkhusha [65] developed a range of novel iRFP proteins
that efficiently combine with endogenous biliverdin, fluorescing without the need for exogenous
biliverdin. Among these new iRFPs, iRFP670 shows the best result for in vivo imaging, and has
since been successfully used for in vivo imaging in a mucosal lung infection model with C. albicans
and Pseudomonas aeruginosa [66]. Due to this, iRFP670 is the most promising reporter exploitable for
in vivo imaging.
Along with the development of fluorescent reporters, microscopy methods have also advanced
for in vivo investigations. Two-photon microscopy [67] allowed study of host–pathogen interactions in
real time and in three dimensions, with high resolution imaging up to a depth of 1 mm [68]. However,
in the original use of this technique, mice had to be anaesthetised and the chest cavity opened to
permit imaging of fungal infections, such as Aspergillus fumigatus [69,70]. Development of two-photon
and multi-photon intravital microscopy [71–73], has provided insights into fungal trafficking and
host–fungal interactions. This relatively new tool has directly imaged targeting of C. neoformans to
the central nervous system and neutrophil removal of the same fungus from the brain vasculature
in vivo [74,75]. Despite the high resolution results and fully developed protocols [71], this technique
is limited to the areas exposed under a surgically-implanted imaging window and cannot yet be
used to image infections in the entire host [72]. As optical technologies and equipment become
better developed and more widespread, these new reporters will supplement the existing palette of
fluorescent proteins, focusing mainly on far red and near infrared reporters. This will allow further
development of high resolution, full body in vivo imaging of fungal infections, allowing researchers to
observe infection progression, or response to therapy, in individual animals.
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